Cohen doesnt think that argument is valid, and Mendias worries it could just fuel more use by being seen as a de facto approval
Bioscience, biotechnology, and biochemistry
FREE OF: Milk, Eggs, Fish, Shellfish, Peanuts, and Wheat
Theres also this recent headline: Which is a touchy subject and I dont want to settle the European regulators investigation (notoriously not overly sensitive about things), but Id venture to say that the psychological impact of obesity and the psychiatric side effects associated with changing body type including dysmorphia and eating disorders probably indicate that this is not a side effect of the drug but rather a side effect of the primary effect of the drug, in a small subset of patients
Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes a Danish nationwide observational study
What are the biggest safety concerns with GLP1 use